Skip to main content
CHE logo

Chemed Corporation (CHE) Stock: Price, Forecast & Analyst Target

Chemed Corporation (CHE) — MoonshotScore 85/100 (Exceptional band), calculated Nov 18, 2026. Price $551.33 (+0.84%), as of the Nov 19, 2026 trading session; market cap $7.15B. Expected results Feb 24, 2027.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and short-term investments: 147.64× (market value Nov 16, 2026; cash Sep 30, 2026) · expected results Feb 24, 2027

$551.33 +$4.61 (+0.84%) Market Cap $7.15B

Chemed Corporation · CHE · NYSE · Healthcare · Medical - Care Facilities

Research dated 2026-09-13 (results through the quarter ended Jun 2026; the quarter ended Sep 2026 not covered): Chemed Corporation operates an unusual combination of completely unrelated businesses under the same corporate roof: a major national hospice care provider and a widespread plumbing and drain cleaning service. Investors weighing the stock must evaluate whether the steady cash flows from the plumbing division will continue to reliably support the specialized, highly regulated operations of the end-of-life medical care segment.

Price as of Nov 19, 2026

Key Statistics

85 of 100

MoonshotScore v2 · Chemed (CHE)

Exceptional
Business Quality Elite (90)
Financial Safety Sound (76)
Valuation Full (54)
Growth Durability Flat (48)
Momentum Surging (87)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality and a strong balance sheet, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Full; Growth Durability: Flat; Momentum: Surging.

  • EPS beat 4 of the last 8 reports
  • Altman Z 9.84 · Piotroski F 7
  • ROE 32.1% · ROA 16.4% · current ratio 1.11 · earnings yield 3.9% · free-cash-flow yield 4.1%

Helping: business quality, balance-sheet strength, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for CHE (57 recorded, newest six shown)
RecordedScoreBand
84Exceptional
84Exceptional
84Exceptional
84Exceptional
85Exceptional
85Exceptional

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$551.33
Change on the day+0.84%
52-week range$365.21–$562.24
Market capitalisation$7.15B
Price / earnings (trailing)26.10
Shares traded on the day236.1K
Beta (volatility vs the S&P 500)0.5
Dividends per share (last 12 months)$2.60
Dividend yield (last 12 months)0.48%

Why Chemed scores 85

Dr. Mira Sol, the Stock Expert AI TV data character
Business Quality carries the score; Growth Durability is what holds it back.
Dr. Mira Sol · Data scientist, Stock Expert AI TV (fictional AI character)
85Exceptional
  • Business Quality90
  • Financial Safety76
  • Valuation54
  • Growth Durability48
  • Momentum87

Share price, last 12 months +22.9%

$446.01 $548.20

What the price assumes

9.7% a year of free-cash-flow growth for ten years is what a $7.15B market value () asks for.

  • Price implies, next ten years9.7%
  • Free cash flow, last 5 years-5.4%
  • Revenue, last 5 years4.0%
  • Analysts' revenue path, 2026–20286.0%

The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.

Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $295.45M. Inputs: FMP statements, estimates and quote.

How the stock reacts to earnings

EPS beat in 5 of the last 12 reports (2024–2026); the stock still fell the next session after 1 of those beats. Average first-session move: 7.6% either way.

  1. +5.1%Feb ’24
  2. -7.0%Apr ’24
  3. -0.1%Jul ’24
  4. -12.0%Oct ’24
  5. +6.4%Feb ’25
  6. -5.6%Apr ’25
  7. -10.6%Jul ’25
  8. +6.6%Oct ’25
  9. -15.3%Feb ’26
  10. +12.9%Apr ’26
  11. +5.9%Jul ’26
  12. +4.0%Oct ’26
Next-session move EPS beat (5) EPS in line (1) EPS miss (6)
Every report, with revenue and five-session moves
Moves run from the close before the report to the first and fifth closes after it.
ReportEPSRevenueNext session5 sessions
BeatIn line+4.0%+4.0%
BeatBeat+5.9%+6.0%
BeatBeat+12.9%+13.9%
MissMiss-15.3%-12.2%
MissMiss+6.6%+0.5%
MissMiss-10.6%-8.2%
BeatIn line-5.6%+0.3%
In lineIn line+6.4%+8.1%
MissMiss-12.0%-12.4%
MissIn line-0.1%+5.3%
MissIn line-7.0%-8.2%
BeatIn line+5.1%+6.4%

Misses cost real money here: the average first-session move after a miss was -6.4%.

What management is saying differently

Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.

  • New this call: “roto rooter”, “ebitda margin”, “adjusted ebitda”, “excluding medicare” — none of them came up in Q2 FY2026.
  • Gone quiet: “water restoration”, “combined program”, “drain cleaning”, “florida combined” — regular themes last call, absent this time.
  • Tone: Cautious words such as “may”, “could” and “headwind” rose from 1.7 to 3.4 per 1,000 words, and confident words such as “record” and “strong” fell from 2.4 to 2.

Management chose more careful words than a quarter earlier. Tone shifts like this often show up in the numbers a quarter or two later.

Our track record on this stock

Since the score went from 83 to 85 while the share price moved +1.8% through .

MoonshotScore (0–100, band floors 45 · 65 · 80) Share price, scaled to its own range

The score has stayed in the Exceptional band across the stretch we have recorded; we grade each band change three months after it happens.

The crowd against our signals

  • Analysts: 50% of 10 rate it a buy; the average target sits +15.2% from the price of $551.33.
  • Last 90 days: 1 upgrade and 0 downgrades among 4 rating actions.
  • Our signals: Exceptional band; strongest pillar Business Quality (90), weakest Growth Durability (48).

Our signals are more constructive than the crowd, led by Business Quality.

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $369, high $553, latest $551. 4 reported quarters marked, 3 above and 1 below the recorded estimate. 1 other dated event marked. $553 $369 high $553 Feb 25, 2026 · Earnings results · reported below the recorded estimate · close $4101Apr 23, 2026 · Earnings results · reported above the recorded estimate · close $4212Jul 28, 2026 · Earnings results · reported above the recorded estimate · close $5323Oct 27, 2026 · Earnings results · reported above the recorded estimate · close $5354Oct 28, 2026 · Earnings call · management outlook · no recorded estimate to compare · close $5355 Oct 17, 2025 Nov 19, 2026 · $551 $441Oct 17, 2025$431Oct 31, 2025$436Nov 14, 2025$439Nov 28, 2025$430Dec 12, 2025$432Dec 26, 2025$444Jan 9, 2026$447Jan 23, 2026$448Feb 6, 2026$475Feb 20, 2026$408Mar 6, 2026$378Mar 20, 2026$381Apr 2, 2026$385Apr 17, 2026$422May 1, 2026$435May 15, 2026$426May 29, 2026$419Jun 12, 2026$463Jun 26, 2026$489Jul 10, 2026$511Jul 24, 2026$553Aug 7, 2026$541Aug 21, 2026$520Sep 4, 2026$504Sep 18, 2026$508Oct 2, 2026$512Oct 16, 2026$535Oct 30, 2026$548Nov 13, 2026

Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Upcoming events

As of

Dated events ahead, in order, not to scaleDec 4, 2026, Dividend payment date; Feb 24, 2027, Next results due. Spacing is order only and carries no duration.Nov 19, 20261Dec 4, 20262Feb 24, 2027
  1. Dividend payment dateCompany record
  2. Next results dueProvider estimate

Management outlook

  • Finally, based on the company's financial results through 09/30/2026, we expect to finish the year at or slightly above the high end of our full year 2026 adjusted EPS guidance discussed in our second quarter 26 earnings press release dated July 28, 2026.

    Michael D. Witzeman · Statement from

How to read these dates

Events are in date order; the spacing is not a duration scale. A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.

What to watch next

Other perspectives

Council score for Chemed (CHE): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Moderate
Valuation Neutral
Growth Durability Neutral
Momentum Strong

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Neutral read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Moderate
Margin of Safety Fairly Valued
Revenue Growth Neutral
ROE Strong

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Chemed (CHE), and what does it report?

Short answer · as of

The company generates revenue from palliative care through its medical segment, deploying physicians, nurses, and clergy to support patients.

Alongside the healthcare operation, it runs a vast network of corporate branches, contractors, and franchisees offering plumbing, excavation, and water restoration services to residential and commercial clients.

Reported financial results merge these disparate operations into a consolidated income statement. While the medical classification dictates how the stock is categorized by data providers, the plumbing segment drives a significant portion of the total revenue, meaning the top line relies heavily on home repair demand as much as it does on hospice admissions.

2 · Latest results

What do the latest results show for Chemed (CHE)?

Recent financial results show steady revenue growth paired with operating profits that routinely exceed analyst estimates for earnings per share. The business consistently generates positive operating cash flow, which easily covers capital expenditures, pointing to a highly cash-generative model across the medical and plumbing segments.

Management frames their forward-looking statements as routine, noting that they recently adjusted their guidance primarily to maintain their historical pattern of updating expectations midway through the calendar cycle. This suggests the underlying operations are performing predictably without forcing emergency revisions.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$690.94M Sep 30, 2026
Latest quarter · SG&A
$111.47M Sep 30, 2026
Latest quarter · FMP standardized operating result
$96.42M Sep 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026$690.94MNot available$111.47M$96.42M
Jun 30, 2026$673.25MNot available$115.20M$89.20M
Mar 31, 2026$657.51MNot available$114.32M$84.58M
Dec 31, 2025$639.34MNot available$105.50M$100.65M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$690.94M Oct 27, 2026
Latest report · revenue estimate
$685.04M Oct 27, 2026
Latest report · revenue vs estimate
Above estimate Oct 27, 2026
Latest report · EPS vs estimate
Above estimate Oct 27, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Oct 27, 2026$690.94M$685.04M$6.7500$6.4400
Jul 28, 2026$673.25M$665.04M$6.0600$5.6000
Apr 23, 2026$657.51M$649.82M$5.6500$5.3000
Feb 25, 2026$639.34M$659.09M$6.4200$7.0200
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2026$691M$72M$5.45 (diluted)
Jun 2026$673M$68M$5.13 (diluted)
Mar 2026$658M$66M$4.85 (diluted)
Dec 2025$639M$77M$5.48 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Chemed (CHE)?

Short answer · as of

Cash and short-term investments were $48.43M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $56.59M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.

The balance sheet carries more total debt than liquid cash and short-term investments, resulting in a net debt position. However, the operations print robust free cash flow, and the company distributes a portion of this cash back to shareholders through regular, recurring dividend payments.

The primary risk comes from the regulatory environment surrounding the hospice segment, where changes to government reimbursement rates or compliance costs would squeeze margins. Concurrently, a severe housing market downturn could stall the plumbing and restoration side, exposing the company to simultaneous pressures across completely different macroeconomic drivers.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
$56.59M Sep 30, 2026
Previous quarter · operating cash flow
$84.81M Jun 30, 2026
Period endOperating cash flowCapital expenditure (reported)
Sep 30, 2026$56.59M−$18.72M
Jun 30, 2026$84.81M−$15.52M
Mar 31, 2026$88.22M−$17.12M
Dec 31, 2025$133.53M−$16.35M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Chemed (CHE)?

Short answer · as of

The next earnings report is expected on Feb 24, 2027. The number it tests is the $25.78 EPS analysts carry for it.

When the company reports its next financial results, analysts will watch whether the medical segment can maintain its profit margins against persistent labor cost pressures in the healthcare sector. Observers will also look for signs that the plumbing division is sustaining its project volume, as any weakness there would dilute the overall earnings momentum.

Following the recent midyear guidance update, attention shifts to how closely actual results track management expectations. Any deviation from the projected path would test the reliability of their forecasting cadence and potentially alter the current trajectory of shareholder returns.

What management is planning

Management's statement is quoted under Upcoming events

5 · Peer comparison

How does Chemed compare with its peers?

Short answer

Chemed's score ranks tied for 4th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Most healthcare facilities are focused entirely on patient care, hospital management, or clinical services. Chemed stands apart by explicitly pairing a highly regulated, labor-intensive medical business with a commercial and residential plumbing service, creating an operational structure rarely seen in public markets.

This structure means the company does not trade on the pure demographic trends typical of a dedicated senior care facility. Instead, its valuation reflects a blend of healthcare stability and the cyclical, weather-dependent nature of emergency home repairs, making direct comparisons to traditional medical providers fundamentally flawed.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
LifeStance Health Group, Inc. (LFST) Same industry, near in market value$13.77 Nov 18, 2026$5.24B92 5-pillar Nov 18, 2026
Universal Health Services, Inc. (UHS) Same industry, near in market value$186.07 Nov 18, 2026$10.7B91 5-pillar Nov 18, 2026
BrightSpring Health Services, Inc. (BTSG) Named competitor$64.02 Nov 19, 2026$12.7B87 5-pillar Nov 18, 2026
Chemed (CHE) — this page$551.33$7.15B85
Option Care Health, Inc. (OPCH) Same industry, near in market value$31.61 Nov 19, 2026$4.74B85 5-pillar Nov 18, 2026
Encompass Health Corporation (EHC) Same industry, near in market value$132.25 Nov 19, 2026$13.0B81 5-pillar Nov 18, 2026
Fresenius Medical Care AG & Co. KGaA (FMS) Same industry, near in market value$20.13 Nov 19, 2026$10.5B80 5-pillar Nov 18, 2026
AptarGroup, Inc. (ATR) Named competitor$140.34 Nov 19, 2026$8.90B77 5-pillar Nov 18, 2026
DaVita Inc. (DVA) Named competitor$156.24 Nov 19, 2026$9.83B76 5-pillar Nov 18, 2026
The Ensign Group, Inc. (ENSG) Same industry, near in market value$176.59 Nov 19, 2026$10.3B74 5-pillar Nov 18, 2026
Henry Schein, Inc. (HSIC) Named competitor$84.80 Nov 19, 2026$9.37B73 5-pillar Nov 18, 2026
Solventum Corporation (SOLV) Same industry, near in market value$85.80 Nov 19, 2026$14.6B66 5-pillar Nov 18, 2026
MiniMed Group, Inc. Common Stock (MMED) Same industry, near in market value$16.26 Nov 19, 2026$4.57B38 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$620.00 – $650.00
Consensus target
$635.00
Median target
$635.00
Revenue estimate
$2.73B
EPS estimate
$25.78

Consensus record · Captured .

Measured against a quoted price of $551.33 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 13, 2026

Transactions
33
Identified insiders
9
Purchases
0
Sales
11
Other transactions
22

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Institutional ownership
99.3% Period end Sep 30, 2026
Reporting holders
550 Period end Sep 30, 2026
Previous quarter · holders
537 Prior to period end Sep 30, 2026
Holders in provider snapshotShares
Blackrock, INC.1,452,540
Aqr Capital Management LLC859,657
Vanguard Portfolio Management LLC855,538
Vanguard Capital Management LLC586,586
Acadian Asset Management LLC461,748

Tracked investors

Which of the 16 named investors we follow held CHE in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.05%$10.70MAdded +3.9% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Chemed (CHE)?

Read these with our analysis →

Common Questions About CHE (Healthcare)

The last 3 questions are answered from this page's own dated data, not from the research.

Which operating division generates the majority of the total revenue?

The medical care operations bring in a larger share of the overall top line compared to the plumbing and drain cleaning side. Even so, the home service division remains a crucial pillar of the business, contributing heavily to the combined financial results.

Why is the business categorized as a healthcare stock when it operates a plumbing service?

Standard industry classifications group stocks based on the largest source of their revenue. Since the palliative care division outearns the home repair segment, the corporate entity sits among medical care facilities. Investors buying the stock for healthcare exposure are also acquiring a major residential and commercial plumbing operation.

How does the non-medical segment manage its nationwide service network?

The plumbing and restoration division reaches customers through a layered structure that includes company-owned branches alongside independent contractors and franchised locations. This model allows the business to perform excavation, water restoration, and drain cleaning for residential and commercial clients across various regions.

What specific types of clinical care does the medical division offer?

Rather than operating traditional hospitals or general practice clinics, the healthcare segment focuses entirely on end-of-life and palliative care. The network deploys physicians, nurses, home health aides, and spiritual clergy to provide direct comfort and emotional counseling to terminally ill patients and their families.

What is the CHE stock price today?

The last price recorded for Chemed Corporation (CHE), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the CHE price target?

The analyst consensus price target for Chemed Corporation (CHE), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Does CHE pay a dividend?

Yes. The dividend yield of Chemed Corporation (CHE) over the last 12 months, with its date, is listed under Price & valuation on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 80 figures on this page — 2 from SEC filings and earnings calls, 67 from Financial Modeling Prep (FMP), 5 with no recorded source, 5 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Sector / industry (provider taxonomy)
  • 1. What is Chemed (CHE), and what does it report?: Business description; Sector / industry (provider taxonomy); Revenue by segment; Quarterly income statement (USD thousands)
  • 2. What do the latest results show for Chemed (CHE)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Chemed (CHE)?: Cash, investments and debt; Cash and short-term investments over time (USD millions); Recent dividends paid; Trailing twelve-month ratio set
  • 4. What should you watch next at Chemed (CHE)?: Next earnings report; Analyst revenue and earnings estimates (average); Management outlook — dated call excerpts; Operating cash flow by quarter (USD millions)
  • 5. How does Chemed compare with its peers?: Business description; Sector / industry (provider taxonomy); Revenue by segment; Trailing twelve-month ratio set
  • FAQ: Which operating division generates the majority of the total revenue?: Revenue by segment; Business description; Annual revenue and net result (USD millions)
  • FAQ: Why is the business categorized as a healthcare stock when it operates a plumbing service?: Sector / industry (provider taxonomy); Revenue by segment; Business description
  • FAQ: How does the non-medical segment manage its nationwide service network?: Business description; Revenue by segment; Sector / industry (provider taxonomy)
  • FAQ: What specific types of clinical care does the medical division offer?: Business description; Sector / industry (provider taxonomy); Revenue by segment
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold CHE

Funds in our ETF coverage that list CHE among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
VictoryShares THB Mid Cap ETF (MDCP)4.00%